Stent placement as a bridge to surgery in malignant biliary obstruction (pancreatic cancer, distal bile duct cancer, and hilar tumors)  by Rodarte-Shade, Mario & Kahaleh, Michel
lable at ScienceDirect
Gastrointest Interv 2015; 4:21–26Contents lists avaiGastrointestinal Intervention
journal homepage: www.gi - intervent ion.orgInvited Review ArticleStent placement as a bridge to surgery in malignant biliary obstruction
(pancreatic cancer, distal bile duct cancer, and hilar tumors)
Mario Rodarte-Shade, Michel Kahaleh*a b s t r a c t
Preoperative biliary drainage (PBD) has been a matter of controversy for years. It was initially aimed to improve the clinical status of patients with
malignant obstructive jaundice prior to surgery. However, its efﬁcacy and safety have not been proven by randomized controlled trials. Most drawbacks of
PBD are related to the increase in procedure-related adverse events and inappropriate biliary decompression. Current trends in PBD show that using self-
expanding metallic stents (SEMSs) may reduce the high incidence of stent-related complications with improved outcomes. The aim of this study was to
review the current literature regarding PBD in patients with resectable distal pancreaticobiliary and hilar tumors.
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Malignant biliary obstruction encompasses a group of neo-
plasms that compromise bile duct ﬂow and clinically presents with
obstructive jaundice. Obstruction can be anatomically classiﬁed as
“distal” or “proximal.” Proximal bile duct obstruction refers to hilar
bile duct cholangiocarcinomas (i.e., Klatskin tumors), whereas
distal bile duct obstruction refers to periampullary tumors. Peri-
ampullary tumors are deﬁned as neoplasms arising from the head
of the pancreas, the distal bile duct, the ampulla of Vater, or the
second portion of the duodenum. Because of the broad range of
tumors, pancreatic cancer by far remains the most common ma-
lignancy in Western countries. During 2014 in the United States,
46,420 patients were expected to be diagnosed with pancreatic
cancer. It is also the fourth most common cause of cancer-related
death among men (after lung cancer, prostate cancer, and colo-
rectal cancer) and among women (after lung cancer, breast cancer,
and colorectal cancer).1 At the time of diagnosis, approximately
only 20% of patients can receive curative surgery.2,3 Hence, most
patients will require palliative decompression.
Preoperative biliary drainage (PBD) is an old concept that was
ﬁrst described in 1935 by Allen O. Whipple.4 Preoperative biliary
drainage emerged as a treatment to counteract the deleterious ef-
fects of biliary obstruction. Literature suggests that performing
surgical resection (i.e., pancreatoduodenectomy) in the setting of
hyperbilirubinemia is associated with higher perioperative mor-
tality.5,6 However, conﬂicting data has been published regarding
the efﬁcacy and safety of routine PBD. The aim of this article was toDivision of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, U
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http://dx.doi.org/10.1016/j.gii.2015.02.003review the existing literature concerning the use of PBD in patients
with resectable distal pancreaticobiliary malignancies. Preopera-
tive biliary drainage in hilar tumor is also discussed separately.
Pathophysiology of biliary obstruction
Biliary obstruction and cholestasis has several deleterious
effects on patient homeostasis. Most evidence comes from exper-
imental studies in animals that received bile duct ligation. Gut
functions are severely impaired in different ways. Jaundiced rats
indicate that intestinal barrier function is compromised.7 Such
impairment has been related to a decreased number and function
of gut mucosal T lymphocytes,8,9 decreased Kupffer cell function,10
increased intestinal permeability,11 impaired cell-mediated im-
munity,12 impaired reticuloendothelial function,13 and altered
mucosal immunity.14 In addition, these gut barrier dysfunctions
have been associated with signiﬁcant bacterial translocation that
may be related to endotoxemia that adversely affects patients with
biliary obstruction.11,15 Other experimental studies in animals and
clinical observations in jaundiced patients have demonstrated a
high concentration of tumor necrosis factor (TNF) and interleukin-
6, which may also contribute to the high morbidity rate of jaun-
diced patients.11,16 In addition to these experimental observations,
obstructive jaundice has been associated with deleterious effects
on the cardiovascular system and on renal function.17–19 Other
detrimental consequences of cholestasis include direct hepatic
injury with altered hepatic protein synthesis20,21 that, in conjunc-
tion with deﬁcient vitamin K absorption, produce coagulationSA
edical College, 1305 York Avenue, 4th Floor, New York, NY 10021, USA.
vier. Open access under CC BY-NC-ND license.
Table 1 The Adverse Effects of Biliary Obstruction
Impaired intestinal barrier function
Decreased number and function of gut mucosal T lymphocytes
Decreased Kupffer cell function
Increased intestinal permeability
Impaired cell-mediated immunity
Impaired reticuloendothelial function
Altered mucosal immunity
Bacterial translocation
Endotoxemia (high TNF and IL-6 levels)
Cardiovascular dysfunction
Renal dysfunction
Direct hepatic injury
Coagulation abnormalities
IL-6, interleukin-6; TNF, tumor necrosis factor.
Gastrointestinal Intervention 2015 4(1), 21–2622abnormalities.22 Animal models have demonstrated most beneﬁts
of PBD; however, the clinical beneﬁts of PBD have not been clearly
established. Table 1 lists the adverse effects of biliary obstruction,
based on animal models and clinical observations.Preoperative biliary drainage versus early surgery
Routine PBD in patients with pancreaticobiliary malignancies
has been a matter of controversy for years. Early studies primarily
included patients who underwent percutaneous biliary drainage.
These studies were mostly represented by retrospective and small
case series with methodological ﬂaws and contradictory results.
Percutaneous transhepatic biliary decompression was initially
described as a safe and potentially helpful procedure that allowed
normalization of hepatic function and theoretically resulted in a
lower operative morbidity in treated patients than in jaundiced
patients.23 Some studies also report that PBD is associated with
reduced mortality, less morbidity, and shorter hospital stays.24–27
By contrast, further early trials showed that routine PBD by
percutaneous methods did not offer any advantage in comparison
to surgery without drainage.28 Furthermore, some publications
report that patients who undergo preoperative percutaneous
transhepatic biliary drainage have an increased rate of complica-
tions resulting from the procedure and do not beneﬁt from pre-
operative drainage.29 The preoperative percutaneous biliary
drainage was also associated with increased hospital cost related to
the procedure and without any clear beneﬁt in operative risk.30
More recent publications include a greater number of patients
who underwent internal drainage by endoscopic retrograde chol-
angiopancreatography (ERCP), and report that patients who un-
derwent PBDdidnothave anydifference in outcomes in comparison
to patients who went directly to surgery.31–33 A retrospective
analysis of 257 patients who underwent pancreatoduodenectomy
showed that a subgroup of 99 patients who had PBD did not have
any difference in morbidity, infectious complications, reoperation
rate, mortality, or long-term survival.31 Another retrospective
cohort reported the outcomes of 311 patients who were submitted
to pancreatoduodenectomy.32 Of these, 232 patients received pre-
operative internal biliary drainage. They were compared to the
patients who underwent immediate surgery (n ¼ 58). The authors
found that PBD did not inﬂuence the incidence of postoperative
complications. A retrospective review of 184 patients of 241
consecutive patientswho underwent surgery showed no signiﬁcant
incidence of postoperative complications between patients who
had preoperative drainage and patients who did not.33
Several studies have not associated PBDwith an increased rate of
complications; however, there are other authors with contradictory
results that claim an increased risk of adverse eventsdprimarily,
infectious complications. Most results come from retrospectivereviews of prospectively collected consecutive series at major
pancreaticobiliary centers.34–39 Research has found that PBD in-
creases the risk of positive intraoperative bile cultures, which also
has been associated with postoperative infectious complications
and a similar microorganism proﬁle.34 Experience with 240 con-
secutives cases of pancreatoduodenectomy performed at the Me-
morial Sloan Kettering Cancer Center (New York, NY, USA) revealed
that PBD (performed in 175 patients)was associatedwith a high rate
of complications, infectious complications, intra-abdominal ab-
scess, and postoperative death.35 A subsequent study from the same
group, which involved 340 consecutive patients who underwent
pancreatoduodenectomy, showed that PBD was associated with a
stent-related complication rate of 23% and a two-fold increase in
postpancreatectomy infectious complications.36 A retrospective
analysis of 567patientswhounderwent pancreatoduodenectomyat
the John Hopkins University School of Medicine (Baltimore, MD,
USA) found that 408 (72%) of patients underwent PBD. The authors
of this analysis found that preoperative biliary stenting did not in-
crease the overall complication rate or mortality rate in patients
who underwent pancreatoduodenectomy; however, stenting did
appear to increase the rate of pancreatic ﬁstula, wound infection,
and bile contamination.37 Another research group found that PBD
was associated with increased operative time, intraoperative blood
loss, and higher incidence of wound infection; however, it did not
increase major morbidity andmortality.38 A group at the University
of Texas MD Anderson Cancer Center (Houston, TX, USA) evaluated
perioperative morbidity and mortality in 300 consecutive patients
who underwent pancreatoduodenectomy.39 The group found that
PBD (performed in 172 patients) did increase the risk of post-
operative wound infection; however, there was no increase in the
risk of major postoperative complications or death.
Several recentmeta-analyses have been published regarding the
controversy of PBD.40–45 Major drawbacks of these meta-analyses
are the inclusion of retrospective series, methodological ﬂaws,
and the inclusion of patients who underwent percutaneous PBD or
endoscopic PBD. Table 2 shows the results of the most recent meta-
analyses.
DRainage vs OPeration (DROP-trial)
A recent multicenter controlled trial randomized patients with
resectable cancer of the pancreatic head to undergo PBD for 4–6
weeks, followed by surgery, or to undergo surgery alone within 1
week after diagnosis.46,47 This Dutch study enrolled 202 patients. It
was conceived to compare the outcome of both strategies. The
primary outcome studied in the trial was the rate of serious com-
plications. The rate of overall serious complications were signiﬁ-
cantly higher in patients who underwent PBD (74% vs. 39%,
P < 0.001). However, there was not a signiﬁcantly increased rate of
surgery-related complications (47% vs. 37%, P ¼ 0.14). In addition,
the mortality and length of stay did not differ between the two
groups. Based on these results, the authors concluded that routine
PBD in patients undergoing surgery for pancreatic cancer increases
the rate of serious complications.
Despite the adequate methodology used in this study, there are
some major drawbacks that need to be considered and have been
previously noted.48 The DROP-trial, which included low-volume
ERCP centers, reports a high number of serious complications in
the PBD group that were mostly related to the drainage procedure.
Endoscopic retrograde cholangiopancreatography is a technically
demanding and potentially high-risk procedure that needs to be
performed in tertiary centers by experienced therapeutic endo-
scopists. In the best scenario, there is a consistently expected failure
rate of up to 10%.49 However, the DROP-trial shows a failure rate of
25% in patients who subsequently required a second drainage
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Mario Rodarte-Shade and Michel Kahaleh / Preoperative Biliary Drainage 23attempt with all potential procedure-derived complications.
Furthermore, most serious complications in the PBD group were
stent-related (e.g., cholangitis, stent occlusion, and need of stent
exchange).
As other authors have reported,48 the high rate of stent-related
complications can be attributed to the use of small plastic stents.
There is increasing evidence that self-expanding metallic stents
(SEMSs) are superior in durability, patency, recurrent biliary
obstruction, and reintervention.50
Indications for PBD
Routine PBD has been a matter of controversy, although there
are some clinical scenarios in which patients with resectable distal
pancreaticobiliary tumors need to undergo biliary drainage.51 Un-
less biliary cannulation cannot be achieved, endoscopic biliary
drainage is always the preferred approach.52 Endoscopic biliary
drainage through endoscopic retrograde cholangiopancreatog-
raphy provides an internal drainage that avoids external drains,
percutaneous transhepatic puncture (i.e., the risk of bleeding or bile
leak), and the risk of tumor seeding at the puncture site. Tumor-
associated cholangitis is an absolute indication for intervention
and should be approached as a medical emergency that requires
prompt biliary decompression and subsequent stent placement.
Indications for PBD are shown in Table 3 and are discussed later.
Delayed surgery
The process by which a patient with malignant biliary obstruc-
tion goes can be long and complex because of logistics, health care
services, waiting lists, referrals, and an extensive diagnostic pro-
tocol. Patients are usually seen at primary or secondary health care
services where the initial evaluation with general laboratory and
imaging are performed. The patient eventually is sent to a tertiary
referral center with a clinical question of or diagnosis of pan-
creaticobiliary malignancy. The treatment of patients at high-
volume referral centers is of major importance because expert
advanced care at these institutions can achieve better outcomes
when treating patients with pancreaticobiliary malignancies.53
Further workup may include other time-consuming imaging
studies such as computed tomography (CT; for staging or pancreatic
imaging protocol), magnetic resonance imagining (MRI), and
endoscopic ultrasound. A pathologic diagnosis is not absolutely
required before surgery; however, patients can undergo different
biopsy protocols that may include CT-guided ﬁne-needle aspiration
biopsy, endoscopic ultrasound-guided ﬁne-needle aspiration,
ERCP-guided biopsy, ductal brushings, cholangioscopy-guided bi-
opsy, or laparoscopic biopsy. Patients will eventually be seen by a
multidisciplinary team that specializes in cancer management, and
will subsequently undergo different consultations (e.g., medicalTable 3 Indications for Preoperative Biliary Drainage
Distal pancreaticobiliary malignancies
Cholangitis
Neoadjuvant treatment
Severe pruritus
Delayed surgery
Routine preoperative biliary drainage (controversial)
Hilar tumors
Cholangitis
NeoVadjuvant treatment
Severe pruritus
Delayed surgery
Right hepatectomy
Portal vein embolization
Routine preoperative biliary drainage (controversial)
Gastrointestinal Intervention 2015 4(1), 21–2624oncologist, pancreaticobiliary surgeon, radiotherapy, and preoper-
ative assessment). Depending on the clinical conditions, patients
will also need to undergo an extensive preoperative assessment
(e.g., cardiovascular/pulmonary clearance). Most patients will need
to improve their clinical condition prior to surgery (e.g., nutritional
status, coagulopathy, and treatment of comorbidities). Waiting lists
and other administrative issuesmay preclude prompt surgery. All of
these factors should be considered when deciding to perform PBD.
An expected delay in deﬁnitive treatment with surgery should be
an indication to perform PBD.
Neoadjuvant therapy
Most pancreaticobiliary malignancies are not resectable at the
moment of diagnosis. However, there is increasing evidence that
neoadjuvant chemoradiation may be useful in patients with
borderline or unresectable pancreatic adenocarcinoma (i.e., locally
advanced disease). Several meta-analyses show that up to one-
third of unresectable locally advanced tumors can be ultimately
resected after neoadjuvant treatment with comparable outcomes
as patients with initially resectable tumors.54,55 Surgery can be
delayed for several months when receiving preoperative chemo-
radiation and in most instances, the administration of chemo-
therapy requires normalization of liver function. Therefore, PBD is
required in these patients prior to neoadjuvant treatment.56
A study evaluated the performance of plastic biliary stents in 49
patients undergoing neoadjuvant chemoradiotherapy for pancre-
atic cancer.57 Themedian time from stent placement to surgery was
150 days (range, 71–227 days). The authors found that up to 55% of
the patients required a repeat ERCP for stent dysfunction and ex-
change.57 Another prospective study assessed the efﬁcacy and
safety of SEMS in 55 patients with resectable or borderline
resectable pancreatic cancer receiving neoadjuvant therapy.56 This
study found that the mean time for neoadjuvant therapy before
surgery was 104 days (range, 70–260 days) and that 88% of the
SEMS remained patent at the end of the therapy. In the end, 49% of
the patients underwent surgery and the presence of the SEMS did
not interfere with surgical resection. These results show that biliary
drainage in patients undergoing neoadjuvant treatment should be
durable to avoid repeat endoscopic procedures. It also suggests that
the best stent for pancreaticobiliary malignancies is the SEMS
because of its high patency rate and low reintervention rate.58
Stent selection: Plastic versus metal
Plastic stents have traditionally been used for temporary
drainage in patients with potentially resectable pancreaticobiliary
malignancy. Plastic stents are inexpensive and can be easily placed
endoscopically without sphincterotomy. The use of the SEMS in
surgical candidates was initially avoided because of the concern
that a metallic foreign body may preclude or have an impact on
surgical resection.59 However, there is increasing evidence that
short uncovered or fully covered SEMS can be safely placed in pa-
tients who will undergo surgery.60–63
Self-expanding metallic stents represent a safe option in pa-
tients undergoing PBD that may signiﬁcantly decrease adverse
events such as stent dysfunction, cholangitis, and the need for
reintervention. However, most studies that claim a high rate of
stent-related complications in PBD have used plastic stents.45,47
Most endoscopic centers typically use 10-Fr plastic stents which
offer an inside lumen diameter of 3.3 mm (0.131 inch). However, a
SEMS can provide an inside diameter of up to 10 mm (0.394 inch),
which is three times greater than the diameter of the plastic
counterpart. A retrospective study compared the outcome of 29
patients who underwent PBD with plastic stents (n ¼ 18) or SEMS(n ¼ 11); endoscopic reintervention was required in 39% of the
plastic stent group awaiting surgery, but no reintervention was
required in the SEMS group.64 Furthermore, a multicenter ran-
domized controlled trial found that SEMS had an longer patency
than plastic stents.65 This study was performed in palliative pa-
tients. However, the time to stent failure was 385 52.5 days in the
SEMS patients and 153.3  19.8 days in the plastic stent patients.65
Another advantage of PBD with SEMS is that no further interven-
tion is required for patients who have unresectable disease (20% of
the patients underwent curative-intent surgery).66
With regard to the individual costs of each stent type (i.e., plastic
vs. SEMS), the SEMS has a higher cost. However, several studies
have assessed the cost-effective strategy of using SEMS in distal
biliary obstruction without regard to surgical resectability. A study
from our group reviewed 101 patients with biliary obstructionwho
underwent SEMS placement.67 A model was developed to compare
the costs of intervention with SEMS and plastic stents (e.g., poly-
ethylene and double-layer stents). Because of the high rate of
reintervention with plastic stents, the routine use of SEMS resulted
in a prolonged patency with less cost. Another study constructed a
Markov model to evaluate the cost and outcomes of four strategies
regarding PBD: (1) an initial plastic stent, followed by a plastic
stent; (2) an initial plastic stent, followed by a SEMS; (3) an initial
SEMS, followed by a plastic stent; and (4) SEMS, followed by a
SEMS. The authors concluded that an initial SEMS that was fol-
lowed by SEMS (if needed) was the less expensive strategy when
approaching patients with pancreatic cancer and unknown surgical
status.68 Hence, the SEMS seems to be a promising option that
should be included in further randomized controlled trials to
effectively assess the value of PBD. At this time, a multicenter
randomized trial comparing coveredmetal stents and plastic stents
for preoperative biliary decompression is under progress
(ClinicalTrials.gov NCT01191814).
Preoperative biliary drainage for hilar tumors
Tumors of the biliary conﬂuence are also known as Klatskin
tumors. As with distal pancreaticobiliary malignancies, obstructive
jaundice is the presenting symptom; the only potential chance of
long-term survival is by surgical resection. Hilar tumors deserve a
separate discussion because to achieve complete surgical resection
most often requires bile duct and major liver resection (i.e., right or
left hepatectomy). Performing liver resections in patients with
obstructive jaundice can carry increased morbidity and mortality;
thus, most major hepatobiliary centers usually offer patients PBD to
improve their clinical condition and outcomes.69 The value of PBD
has been acknowledged as part of “preoperative liver optimization”
in conjunctionwith portal vein embolization. These actions prevent
postoperative acute liver failure and improve postoperative out-
comes in patients with hilar tumors.70
As with distal pancreaticobiliary malignancies, routine PBD for
hilar tumors is controversial. A recent systematic review of the
literature included 10 studies with 442 patients who underwent
routine PBD and 233 patients who did not have PBD. This meta-
analysis could not provide evidence of a clinical beneﬁt of using
routine PBD in obstructive jaundice secondary to hilar tumors.71
However, there are some clinical scenarios in which PBD may be
an acceptable approach. First, cholangitis is an absolute indication
for PBD. Another indication for PBD includes patients who undergo
right hepatectomy (for Bismuth type IIIA or IV hilar chol-
angiocarcinoma). A recent European multicenter retrospective
analysis reviewed the outcomes of 366 patients with hilar chol-
angiocarcinoma inwhom 180 PBD procedures were performed.72,73
The authors of this analysis found that PBD did not affect the overall
mortality in patients with hilar cholangiocarcinoma; however, PBD
Mario Rodarte-Shade and Michel Kahaleh / Preoperative Biliary Drainage 25was associated with a decreased mortality rate after right hepa-
tectomy and an increased mortality rate after left hepatectomy. The
data show that patients with PBD and hilar cholangiocarcinoma
who underwent left hepatectomy had a higher rate of septic
complications. By contrast, patients who underwent right hepa-
tectomy had a lower rate of liver failure. These observations may be
related to the fact that the residual right liver in patients with left
hepatectomy is larger than the smaller residual left liver after right
hepatectomy.72,73 In addition, after right hepatectomy, a high level
of serum bilirubin was also associated with increased mortality.72
This ﬁnding reﬂects the importance of PBD in selected cases of
patients with hilar tumors.74,75 Other indications for PBD include
patients who will undergo neoadjuvant chemoradiation, patients
who will receive portal vein embolization (i.e., “preoperative liver
optimization”), and patients with severe intractable pruritus.73
Table 3 shows the indications of PBD in patients with hilar tumors.
Techniques for PBD in patients with hilar tumors can also be
divided into percutaneous or endoscopic approaches. Current
techniques are percutaneous transhepatic biliary drainage, endo-
scopic nasobiliary drainage, and endoscopic biliary drainage. The
choice of any given approach depends on center experience, patient
condition, and the ability to cannulate and gain access to the hilar
tumor. However, a recent retrospective study reviewed 141 patients
with hilar tumor that underwent percutaneous PBD or endoscopic
PBD.76 The authors of this study found an oncological beneﬁt and
improved prognosis with the endoscopic approach. Patients who
underwent the percutaneous approach had a higher rate of perito-
neal tumor seeding and poor survival, compared to the endoscopic
approaches. Increasing evidence has been published regarding
tumor seedingwhen using the percutaneous transhepatic approach
(up to 5–20%).74,75 Therefore, endoscopic biliary drainage (e.g.,
nasobiliary drainage or transpapillary drainage) represents the best
approach when performing PBD in patients with hilar tumors.73
Endoscopic drainage can be accomplished by endoscopic naso-
biliary drainage (ENBD) or by endoscopic retrograde biliary
drainage (ERBD). Both techniques seem to effectively achieve
adequate biliary drainage. However, there are some aspects to be
considered. Endoscopic retrograde biliary drainage represents a
more physiological drainage procedure; however, it seems to be
associated with a higher rate of complications and duodenobiliary
reﬂux that may be related to a higher degree of inﬂammatory re-
action in the bile ducts. By contrast, the major drawbacks of ENBD
are patient discomfort and tube dislodgement.73 To date, there is no
consensus regarding which is the optimal endoscopic technique.
Conclusion
Biliary obstruction in patients with pancreaticobiliary malig-
nancies results in several deleterious effects on patient physiology.
Routine PBD has been proposed to counteract these adverse effects;
however, its efﬁcacy has not been completely proven because of the
high rate of procedure-related adverse events. However, the use of
SEMSs may reduce the incidence of adverse events related to PBD
and eventually improve postoperative outcomes. The current ab-
solute indications for PBD in patients with distal pancreaticobiliary
malignancies are cholangitis, an expected delay in surgery, and
patients with a borderline or unresectable pancreaticobiliary ma-
lignancy who are receiving neoadjuvant therapy. Furthermore, in-
dications for preoperative drainage in patients with hilar tumors
include cholangitis, patients who have undergone right hepatec-
tomy, and patients receiving neoadjuvant chemoradiation and/or
portal vein embolization. Further well-designed randomized
controlled trials are required to assess the efﬁcacy and safety of PBD
in patients with distal pancreaticobiliary malignancies and hilar
tumors.Conﬂicts of interest
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